| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
Sulfadimethoxine sodium targets the bacterial enzyme dihydropteroate synthase (DHPS), a key enzyme in the folate biosynthesis pathway. By inhibiting DHPS, the compound blocks the conversion of para-aminobenzoic acid (PABA) to dihydropteroate, an essential intermediate in folic acid synthesis. This inhibits the production of folic acid, which is necessary for bacterial DNA synthesis and cell division. The compound is a sulfonamide antibiotic, and its mechanism of action is similar to other sulfonamides.
|
|---|---|
| ln Vitro |
Sulfadimethoxine sodium exhibits in vitro antibacterial activity against a range of bacterial strains. Its activity is assessed using standard broth microdilution or agar diffusion methods to determine minimum inhibitory concentrations (MICs). The compound’s long-lasting antimicrobial effect makes it suitable for veterinary applications. These in vitro studies confirm its potential as an antibacterial agent.
|
| ln Vivo |
Sulfadimethoxine sodium is used in vivo as a veterinary antimicrobial drug. It is used for the treatment of bacterial infections in animals and as an approved aquaculture antimicrobial. The compound’s long-lasting effect allows for convenient dosing regimens. Its efficacy depends on the susceptibility of the infecting organism and the ability to achieve adequate drug concentrations at the site of infection.
|
| Enzyme Assay |
In vitro enzyme assays for Sulfadimethoxine sodium involve measuring its inhibition of dihydropteroate synthase (DHPS). These assays typically use recombinant DHPS from bacteria. The enzyme is incubated with its substrates (pteridine and PABA) and varying concentrations of the compound. The production of dihydropteroate is measured. These assays confirm that Sulfadimethoxine sodium is a competitive inhibitor of DHPS.
|
| Cell Assay |
In vitro cellular assays for Sulfadimethoxine sodium are conducted using bacterial cultures. Susceptible bacterial strains are cultured in appropriate media and treated with varying concentrations of the compound. Bacterial growth is monitored by optical density, and the minimum inhibitory concentration (MIC) is determined. Cytotoxicity assays in mammalian cell lines may be performed to assess selectivity.
|
| Animal Protocol |
In vivo animal experiments with Sulfadimethoxine sodium are conducted in animal models of bacterial infection. Rodent models of systemic infection or urinary tract infection are commonly used. Animals are infected with a pathogenic bacterial strain, and the compound is administered orally or by injection at varying doses. Efficacy endpoints include survival rates, bacterial load in tissues, and clinical signs of infection. These studies define the compound’s in vivo efficacy and optimal dosing.
|
| ADME/Pharmacokinetics |
Sulfadimethoxine sodium is well absorbed after oral administration and has a long half-life, allowing for once-daily dosing. It is metabolized in the liver, primarily by acetylation, and excreted in the urine. The compound distributes widely throughout body tissues and fluids. Its long-acting nature makes it useful for veterinary applications.
|
| Toxicity/Toxicokinetics |
Dosage adjustments may be necessary in patients with impaired renal function. Common adverse effects of sulfadimethoxine sodium are similar to other sulfonamides and include hypersensitivity reactions, hematological effects, and renal toxicity. The compound is contraindicated in patients with known sulfonamide hypersensitivity. In veterinary use, appropriate withdrawal periods must be observed to ensure food safety.
|
| Additional Infomation |
Sulfadimethoxine sodium is an organic molecular entity. See also: Sulfadimethoxine (with active moiety).
Sulfadimethoxine sodium is a sulfonamide antibiotic used for veterinary applications. It is also known as sodium sulfadimethoxine. The compound is a dihydropteroate synthase inhibitor with a long-lasting antimicrobial effect. It is used as an approved aquaculture antimicrobial and for the detection of antibiotic residues in milk. Sulfadimethoxine sodium is available in high purity for research applications. Its long-acting nature provides advantages for veterinary dosing regimens. |
| Molecular Formula |
C12H13N4NAO4S
|
|---|---|
| Molecular Weight |
332.3108
|
| Exact Mass |
332.055
|
| CAS # |
1037-50-9
|
| Related CAS # |
Sulfadimethoxine;122-11-2;Sulfadimethoxine-d4;1020719-80-5;Sulfadimethoxine-d6;73068-02-7
|
| PubChem CID |
13384041
|
| Appearance |
White to off-white solid powder
|
| Density |
1.441g/cm3
|
| Boiling Point |
548.5ºC at 760mmHg
|
| Melting Point |
268 °C
|
| Flash Point |
285.5ºC
|
| Vapour Pressure |
4.41E-12mmHg at 25°C
|
| LogP |
2.397
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
22
|
| Complexity |
425
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
DQDZQHMCPDUUPC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H13N4O4S.Na/c1-19-11-7-10(14-12(15-11)20-2)16-21(17,18)9-5-3-8(13)4-6-9;/h3-7H,13H2,1-2H3;/q-1;+1
|
| Chemical Name |
sodium;(4-aminophenyl)sulfonyl-(2,6-dimethoxypyrimidin-4-yl)azanide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~752.31 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.26 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.26 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0092 mL | 15.0462 mL | 30.0924 mL | |
| 5 mM | 0.6018 mL | 3.0092 mL | 6.0185 mL | |
| 10 mM | 0.3009 mL | 1.5046 mL | 3.0092 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
